New chairman revealed at pharma firm

The new chairman of Burton pharma firm Clinigen has been revealed this morning (September 1).

Peter Allen will leave the company, to be replaced as chair by Elmar Schnee.

Schnee most recently served on the board of Jazz Pharmaceuticals, since 2014. He works as a non-executive director on a number of other pharmaceutical company boards, including Santhera AG and Calliditas AB, alongside several other private biopharma companies.

Shaun Chilton, chief executive officer of Clinigen, said: “I would like to thank Peter on behalf of the Board, and personally, for his valued leadership and contributions since Clinigen’s IPO in 2012. I have enjoyed working with Elmar to date and look forward to working more closely with him as we continue to grow the company and deliver value.”

Schnee said: “Clinigen has built a strong global business that is uniquely well-positioned to provide an end-to-end service to pharmaceutical clients. I look forward to continuing to work with the Board and management as we build upon the company’s successes to date and realise the full potential of its lifecycle platform.”

Allen added: “I am proud to have spent nine years as chairman of Clinigen. During that time the Company has grown and developed into a global leader in providing global access to medicines, delivering significant value to patients, customers and shareholders. I have every confidence in Clinigen’s continued success.”